MECHELEN, BELGIUM--(Marketwired - Apr 8, 2013) -
Post# of 28539
Posted On: 04/08/2013 6:45:07 PM
MECHELEN, BELGIUM--(Marketwired - Apr 8, 2013) -
Mechelen, Belgium; 8 April 2013 - Galapagos NV (Euronext: GLPG) announced
today a capital increase arising from employee warrant exercises.
Since its inception in 1999, Galapagos has used warrant plans to
incentivize personnel and management and have them share in the success of
the company. Following warrant exercises during the exercise period from 9
March 2013 through 29 March 2013, Galapagos issued 197,581 new ordinary
shares on 5 April 2013 for a total capital increase (including issuance
premium) of EUR1,181,926.39.
CEO Onno van de Stolpe exercised 50,000 warrants, granted in 2008 and which
were due to expire on 25 June 2013. Of these, 20,000 were exercised through
a cashless exercise facility to finance the cash exercise of 30,000
warrants. Onno van de Stolpe's shareholding in Galapagos thereby increased
by 30,000 shares to a total of 355,448 shares, or 1.32% of the outstanding
Galapagos shares.
To date, Galapagos' total share capital amounts to EUR145,884,501.48; the
total number of securities conferring voting rights is 26,968,328, which is
also the total number of voting rights (the "denominator"), and all
securities conferring voting rights and all voting rights are of the same
category. The total number of rights (warrants) to subscribe to not yet
issued securities conferring voting rights is 3,123,368, which equals the
total number of voting rights that may result from the exercise of these
warrants. Galapagos does not have any convertible bonds or shares without
voting rights outstanding.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-
action, with a large pipeline of four clinical, six pre-clinical, and 30
discovery small-molecule and antibody programs in cystic fibrosis,
inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
treatment of rheumatoid arthritis and potentially other inflammatory
diseases, about to enter Phase 2b studies. AbbVie and Galapagos signed a
worldwide license agreement whereby AbbVie will be responsible for further
development and commercialization after Phase 2b. Galapagos has another
selective JAK1 inhibitor in Phase 2 in lupus and psoriasis, GSK2586184
(formerly GLPG0778, in- licensed by GlaxoSmithKline in 2012). GLPG0187 is a
novel integrin receptor antagonist currently in a Phase 1b patient study in
metastasis. GLPG0974 is the first inhibitor of FFA2 to be evaluated
clinically for the treatment of IBD; this program will start a Proof of
Concept Phase 2 study in Q2 2013. The Galapagos Group, including fee-for-
service companies BioFocus, Argenta and Fidelta, has around 800 employees
and operates facilities in five countries, with global headquarters in
Mechelen, Belgium. Further information at: www.glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"could," "stands to," and "continues," as well as similar expressions. Such
forward- looking statements may involve known and unknown risks,
uncertainties and other factors which might cause the actual results,
financial condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future results,
financial conditions, performance or achievements expressed or implied by
such forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events, conditions
or circumstances on which any such statement is based, unless required by
law or regulation.
Galapagos increases share capital through warrant exercises:
http://hugin.info/133350/R/1691280/555372.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1691280]
CONTACT
Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240Email Contact
View More
Mechelen, Belgium; 8 April 2013 - Galapagos NV (Euronext: GLPG) announced
today a capital increase arising from employee warrant exercises.
Since its inception in 1999, Galapagos has used warrant plans to
incentivize personnel and management and have them share in the success of
the company. Following warrant exercises during the exercise period from 9
March 2013 through 29 March 2013, Galapagos issued 197,581 new ordinary
shares on 5 April 2013 for a total capital increase (including issuance
premium) of EUR1,181,926.39.
CEO Onno van de Stolpe exercised 50,000 warrants, granted in 2008 and which
were due to expire on 25 June 2013. Of these, 20,000 were exercised through
a cashless exercise facility to finance the cash exercise of 30,000
warrants. Onno van de Stolpe's shareholding in Galapagos thereby increased
by 30,000 shares to a total of 355,448 shares, or 1.32% of the outstanding
Galapagos shares.
To date, Galapagos' total share capital amounts to EUR145,884,501.48; the
total number of securities conferring voting rights is 26,968,328, which is
also the total number of voting rights (the "denominator"), and all
securities conferring voting rights and all voting rights are of the same
category. The total number of rights (warrants) to subscribe to not yet
issued securities conferring voting rights is 3,123,368, which equals the
total number of voting rights that may result from the exercise of these
warrants. Galapagos does not have any convertible bonds or shares without
voting rights outstanding.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-
action, with a large pipeline of four clinical, six pre-clinical, and 30
discovery small-molecule and antibody programs in cystic fibrosis,
inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
treatment of rheumatoid arthritis and potentially other inflammatory
diseases, about to enter Phase 2b studies. AbbVie and Galapagos signed a
worldwide license agreement whereby AbbVie will be responsible for further
development and commercialization after Phase 2b. Galapagos has another
selective JAK1 inhibitor in Phase 2 in lupus and psoriasis, GSK2586184
(formerly GLPG0778, in- licensed by GlaxoSmithKline in 2012). GLPG0187 is a
novel integrin receptor antagonist currently in a Phase 1b patient study in
metastasis. GLPG0974 is the first inhibitor of FFA2 to be evaluated
clinically for the treatment of IBD; this program will start a Proof of
Concept Phase 2 study in Q2 2013. The Galapagos Group, including fee-for-
service companies BioFocus, Argenta and Fidelta, has around 800 employees
and operates facilities in five countries, with global headquarters in
Mechelen, Belgium. Further information at: www.glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"could," "stands to," and "continues," as well as similar expressions. Such
forward- looking statements may involve known and unknown risks,
uncertainties and other factors which might cause the actual results,
financial condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future results,
financial conditions, performance or achievements expressed or implied by
such forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events, conditions
or circumstances on which any such statement is based, unless required by
law or regulation.
Galapagos increases share capital through warrant exercises:
http://hugin.info/133350/R/1691280/555372.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1691280]
CONTACT
Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240Email Contact
View More
(0)
(0)
test